Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Cash-to-Debt : 164.99 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zynerba Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2023 was 164.99.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zynerba Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Zynerba Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ZYNE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31 Med: 512.76 Max: No Debt
Current: 164.99

During the past 10 years, Zynerba Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.31. And the median was 512.76.

ZYNE's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.945 vs ZYNE: 164.99

Zynerba Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Zynerba Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zynerba Pharmaceuticals Cash-to-Debt Chart

Zynerba Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

197.92

537.79

120.44

151.17

Zynerba Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															139.18	142.69	151.17	160.87	164.99

Competitive Comparison of Zynerba Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Zynerba Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zynerba Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zynerba Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zynerba Pharmaceuticals's Cash-to-Debt falls into.

Zynerba Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zynerba Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	50.641	/	(0.215	+	0.12)
	=	151.17

Zynerba Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	35.968	/	(0.218	+	0)
	=	164.99

Zynerba Pharmaceuticals (NAS:ZYNE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zynerba Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333

Website

http://www.zynerba.com

Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Executives

Kenneth T Jones	officer: See Remarks	C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger	officer: VP, Commercial & Business Dev.	C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree	officer: President	ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher	officer: Chief Financial Officer	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido	director, officer: Chairman & Chief Exec. Officer	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch	director	68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper	director	NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson	director	C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner	director	2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici	director	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker	officer: Chief Legal Officer	C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon	officer: Sec, General Counsel & VP HR	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp	10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison	director